Moderna Soars 10% on Oncology, CAR-T and Autoimmune Research Unveilings

MRNA•2026-06-26

Moderna shares rose nearly 10% on Friday after its Science Day unveiled oncology and CAR-T programs and new autoimmune disorder research. The stock has climbed roughly 40% over the past month, reaching a 52-week high as healthcare sector gains accelerate.

1. Science Day Presentation

At its recent Science Day event, Moderna detailed a strategy to diversify beyond COVID-19 vaccines by advancing oncology candidates, exploring CAR-T applications and launching early-stage autoimmune disorder research programs.

2. Stock Performance

Shares jumped nearly 10% on the day, extending a roughly 40% gain over the past month and pushing the stock to a fresh 52-week high as healthcare and biotech equities rallied.

3. Pipeline Diversification Strategy

Moderna plans to leverage its mRNA platform across multiple therapeutic areas, building a portfolio that spans oncology, autoimmune diseases and next-generation mRNA therapies to drive long-term growth.